Drug Profile
Encukalner - Xenon Pharmaceuticals
Alternative Names: 1OP 2198; VRX 621698; XEN-1101; XPF-008Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Bausch Health Companies
- Developer Icahn School of Medicine at Mount Sinai; Xenon Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Partial epilepsies; Tonic-clonic epilepsy
- Phase II Major depressive disorder
- No development reported Epilepsy
Most Recent Events
- 29 Feb 2024 Xenon Pharmaceuticals announces its intention to hold an end-of-phase II meeting with the US FDA for Major depressive disorder, in April 2024
- 29 Feb 2024 Xenon Pharmaceuticals plans a first phase III trial for Major depressive disorder (PO) in the second half of 2024
- 02 Dec 2023 Updated efficacy and safety data from the phase IIb X-TOLE trial in Partial epilepsies released by Xenon Pharmaceuticals